MAP2 and neoplasm: Accordingly, we ablated the neural generating capabilities of the human CSCs by MAP2 RNAi (5′ end RNAi: shRNA1 and 3′ end RNAi: shRNA2; Figure 6A–C) to explore the involvement of neurons derived from the human CSCs in tumor progression.